IN THE NEWS
Mayne Pharma Announces Strategic investment in US Facilities
ABOUT US
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to clients worldwide...
NEWS AND EVENTS
Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published U.S. FDA APPROVES NEXTSTELLIS ®, NEW ORAL CONTRACEPTIVE FDA approval of novel oral contraceptive NEXTSTELLIS® New data on NEXTSTELLIS® presented at ISSWSH conference Mayne Pharma launches Microgestin® 24 Fe tablets in the United States
PARTNERING
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...
SPECIALTY TECHNOLOGIES
Mayne Pharma has a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world...
FOR INVESTORS
| Last Updated: | |
ASX: |
1.05 AUD |
| Change: / | Open: |
| Low: | High: |
| Close: | Volume: |
| Market Cap: | 52 Week: - |